Insights from 2023 ESMO Annual Meeting
ESMO 2023 Insights: "CABASTY Trial - Pain Response and HRQL Analysis in Patients With mCRPC Receiving Cabazitaxel Every 2 Weeks vs. Every 3 Weeks"
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Stéphane Oudard
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Stéphane Oudard
Login to view comments.
Click here to Login
Genitourinary